The mission of the NRG Oncology Statistics and Data Management Center (SDMC) is to provide all necessary expertise and personnel for the design, conduct and analysis of clinical trials and associated research for NRG Oncology, a member group of the NCI National Clinical Trials Network (NCTN) program. The Statistics Core of the SDMC provides statistical methodology expertise for the conduct of cancer clinical trials and associated research. The Statistics Core is an integral component central to the SDMC and to NRG Oncology as a whole. Statisticians represent the most closely collaborating group within the SDMC with NRG Oncology investigators across the disease sites that the group addresses. In the first cycle (2014-2019) of the NCTN, the NRG Oncology SDMC was successfully formed from existent centers with specific areas of expertise, both in the disease sites and the attendant trial methodology. The SDMC has retained this expertise, but also broadened individuals? roles so that statisticians may engage in new disease sites, trial methodology, and analytic methods. This unification and expansion has strengthened the statistics group. During the first cycle, the statistics group enjoyed a highly productive period, supporting the initiation of 32 new trials and obtaining final approval on an additional 14 trials now in development, while continuing to maintain accrual and/or follow-up to primary and secondary endpoint reporting on over 80 additional trials that were active at the inception of NRG Oncology. With respect to contributions to the total NCTN effort, the accruing NRG Oncology trials during 2014-2017 represent 34% of all accruing NCTN trials. Publications from the group in the first cycle number over 300, including 39 statistics and clinical trials methodology articles by SDMC statisticians. In the second cycle of the NCTN, the Statistics Core will continue to carry out its critical trial conduct functions, beginning with trial design appropriate for the question, using innovative modern methods to develop efficient and maximally informative trials. Approaches such as integrated trial developmental phases and incorporation of modern biomarker-based information will be sought. Analysis plans for primary, secondary, and exploratory aims will reflect state-of-the-art statistical methodology, with novel methods developed as needed. The Statistics Core, working with other components of the SDMC, will provide continuous trial conduct oversight through all stages from concept and protocol development, trial monitoring, initial reporting, and publication. The statisticians will work closely with SDMC data management and information technology personnel to assure secure high-quality data collection, maintenance, and curation for additional discovery and data sharing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180822-06
Application #
9628263
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-03-28
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Timmerman, Robert D; Hu, Chen; Michalski, Jeff M et al. (2018) Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol 4:1287-1288
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Boardman, Cecelia H; Brady, William E; Dizon, Don S et al. (2018) A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic On Gynecol Oncol 151:202-207
Blumenthal, Deborah T; Won, Minhee; Mehta, Minesh P et al. (2018) Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro Oncol 20:966-974
Hu, Chen; Steingrimsson, Jon Arni (2018) Personalized Risk Prediction in Clinical Oncology Research: Applications and Practical Issues Using Survival Trees and Random Forests. J Biopharm Stat 28:333-349
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancerĀ treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Felix, Ashley S; Cohn, David E; Brasky, Theodore M et al. (2018) Receipt of adjuvant endometrial cancer treatment according to race: anĀ NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol 219:459.e1-459.e11
Burger, Robert A; Deng, Wei; Makker, Vicky et al. (2018) Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 150:466-470

Showing the most recent 10 out of 331 publications